Antibodies that bind to epha2 and methods of use thereof
AssigneeMacroGenics, Inc.
InventorsJennie P. MATHER, Penelope E. Roberts
Life of this patent
Estimating the term…
Abstract
Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed.
Claims29
1-23. (canceled)
A method of treating cancer in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an EphA2 antibody that specifically binds to EphA2;
- wherein the EphA2 antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody LUCA19 produced by the cell line having ATCC No. PTA-5070.
A method of treating cancer in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an EphA2 antibody that specifically binds to EphA2;
- wherein the EphA2 antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody SPL1 produced by the cell line having ATCC No. PTA-6059.
A method of treating cancer in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an EphA2 antibody that specifically binds to EphA2;
- wherein the EphA2 antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody LUCA40 produced by the cell line having ATCC No. PTA-6056.
A method of treating cancer in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an EphA2 antibody that specifically binds to EphA2;
- wherein the EphA2 antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody SG5 produced by the cell line having ATCC No. PTA-7356.
Dependencies are inferred from the claim text.